| 000 | 01727 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250517183746.0 | ||
| 264 | 0 | _c20190708 | |
| 008 | 201907s 0 0 eng d | ||
| 022 | _a1533-3450 | ||
| 024 | 7 |
_a10.1681/ASN.2017070734 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSeitz-Polski, Barbara | |
| 245 | 0 | 0 |
_aPhospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy. _h[electronic resource] |
| 260 |
_bJournal of the American Society of Nephrology : JASN _c02 2018 |
||
| 300 |
_a401-408 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAutoantibodies _xblood |
| 650 | 0 | 4 |
_aAutoantigens _ximmunology |
| 650 | 0 | 4 |
_aEpitopes _xdrug effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlomerulonephritis, Membranous _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aReceptors, Phospholipase A2 _ximmunology |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 |
_aRituximab _xtherapeutic use |
| 700 | 1 | _aDebiec, Hanna | |
| 700 | 1 | _aRousseau, Alexandra | |
| 700 | 1 | _aDahan, Karine | |
| 700 | 1 | _aZaghrini, Christelle | |
| 700 | 1 | _aPayré, Christine | |
| 700 | 1 | _aEsnault, Vincent L M | |
| 700 | 1 | _aLambeau, Gérard | |
| 700 | 1 | _aRonco, Pierre | |
| 773 | 0 |
_tJournal of the American Society of Nephrology : JASN _gvol. 29 _gno. 2 _gp. 401-408 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1681/ASN.2017070734 _zAvailable from publisher's website |
| 999 |
_c27764931 _d27764931 |
||